Rajwinder Lehal

896 total citations
19 papers, 562 citations indexed

About

Rajwinder Lehal is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Rajwinder Lehal has authored 19 papers receiving a total of 562 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Oncology and 2 papers in Organic Chemistry. Recurrent topics in Rajwinder Lehal's work include Cancer Cells and Metastasis (3 papers), Ubiquitin and proteasome pathways (3 papers) and Cancer-related gene regulation (3 papers). Rajwinder Lehal is often cited by papers focused on Cancer Cells and Metastasis (3 papers), Ubiquitin and proteasome pathways (3 papers) and Cancer-related gene regulation (3 papers). Rajwinder Lehal collaborates with scholars based in Switzerland, United States and Spain. Rajwinder Lehal's co-authors include Freddy Radtke, Ute Koch, Jeff C. Liu, Tao Deng, Jinny Kim, Eldad Zacksenhaus, Patrick C. Fraering, Dirk Beher, Thomas Lemmin and Matteo Dal Peraro and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Rajwinder Lehal

18 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rajwinder Lehal Switzerland 10 368 204 78 63 51 19 562
Lucile Canterel-Thouennon France 9 273 0.7× 242 1.2× 141 1.8× 40 0.6× 42 0.8× 10 537
Ryan Ward Canada 7 472 1.3× 272 1.3× 105 1.3× 138 2.2× 35 0.7× 11 667
Sara Nik United States 10 456 1.2× 132 0.6× 110 1.4× 39 0.6× 20 0.4× 10 590
Françoise Pujol France 14 417 1.1× 182 0.9× 116 1.5× 67 1.1× 16 0.3× 18 629
Jun‐ichi Suehiro Japan 13 346 0.9× 101 0.5× 88 1.1× 32 0.5× 32 0.6× 22 526
Anuradha Poonepalli Singapore 14 501 1.4× 152 0.7× 102 1.3× 94 1.5× 26 0.5× 18 687
Nalle Pentinmikko Finland 9 509 1.4× 129 0.6× 123 1.6× 52 0.8× 31 0.6× 12 740
Joachim Theilhaber United States 11 406 1.1× 154 0.8× 50 0.6× 116 1.8× 24 0.5× 18 634
Jessica Gosio Canada 4 232 0.6× 167 0.8× 47 0.6× 26 0.4× 55 1.1× 5 473
Nan Sethakorn United States 14 303 0.8× 117 0.6× 63 0.8× 28 0.4× 19 0.4× 24 464

Countries citing papers authored by Rajwinder Lehal

Since Specialization
Citations

This map shows the geographic impact of Rajwinder Lehal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajwinder Lehal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajwinder Lehal more than expected).

Fields of papers citing papers by Rajwinder Lehal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajwinder Lehal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajwinder Lehal. The network helps show where Rajwinder Lehal may publish in the future.

Co-authorship network of co-authors of Rajwinder Lehal

This figure shows the co-authorship network connecting the top 25 collaborators of Rajwinder Lehal. A scholar is included among the top collaborators of Rajwinder Lehal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajwinder Lehal. Rajwinder Lehal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Vigolo, Michele, Sébastien Lamy, Jovanny Zabaleta, et al.. (2023). The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer. Cancers. 15(15). 3957–3957. 9 indexed citations
2.
Medinger, Michael, Dominik Heim, Alexandar Tzankov, et al.. (2022). CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL. SHILAP Revista de lepidopterología. 3(3). 1009–1012. 13 indexed citations
3.
Adhikari, Manish, Tânia Amorim, Kevin McAndrews, et al.. (2021). Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Research. 81(19). 5102–5114. 24 indexed citations
4.
Miranda, Elena, Anastasios Stathis, Dagmar Hess, et al.. (2021). Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.. Journal of Clinical Oncology. 39(15_suppl). 3020–3020. 18 indexed citations
5.
Fabbro, Doriano, Michael Bauer, Maximilien Murone, & Rajwinder Lehal. (2020). Notch Inhibition in Cancer: Challenges and Opportunities. CHIMIA International Journal for Chemistry. 74(10). 779–779. 11 indexed citations
6.
García, José Manuel Pérez, Javier Cortés, Elena Miranda, et al.. (2020). 562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex. Annals of Oncology. 31. S484–S485. 1 indexed citations
7.
Weber, Dirk, Rajwinder Lehal, Viktoras Frismantas, et al.. (2018). Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor targeting the NOTCH transcription complex. Annals of Oncology. 29. iii14–iii14. 3 indexed citations
8.
9.
García, José Manuel Pérez, Javier Cortés, Anastasios Stathis, et al.. (2018). First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. Journal of Clinical Oncology. 36(15_suppl). TPS2619–TPS2619. 9 indexed citations
10.
Spriano, Filippo, Chiara Tarantelli, Alberto J. Arribas, et al.. (2018). Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103. Molecular Cancer Therapeutics. 17(1_Supplement). B061–B061. 4 indexed citations
11.
Lehal, Rajwinder, Viktoras Frismantas, Jean‐Pierre Bourquin, et al.. (2017). Pharmacological Activity Of Cb-103-An Oral Pan-Notch Inhibitor With A Novel Mode Of Action. Haematologica. 102. 29–29. 1 indexed citations
12.
Lehal, Rajwinder, Viktoras Frismantas, Jean‐Pierre Bourquin, et al.. (2017). Pharmacological activity of CB-103: An oral pan-NOTCH inhibitor with a novel mode of action. Annals of Oncology. 28. v137–v137. 4 indexed citations
13.
Lehal, Rajwinder, Viktoras Frismantas, Jean‐Pierre Bourquin, et al.. (2017). PHARMACOLOGICAL ACTIVITY OF CB‐103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL PAN‐NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION. Hematological Oncology. 35(S2). 46–46. 4 indexed citations
14.
Dimitrov, Mitko, Thomas Lemmin, Rajwinder Lehal, et al.. (2013). Alzheimer’s disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production. Nature Communications. 4(1). 2246–2246. 73 indexed citations
15.
Koch, Ute, Rajwinder Lehal, & Freddy Radtke. (2013). Stem cells living with a Notch. Development. 140(4). 689–704. 211 indexed citations
16.
Radtke, Freddy, et al.. (2012). Notch Signaling In Normal And Malignant T-Cells. Experimental Hematology. 40(8).
17.
Smith, Emma, Stéphanie Claudinot, Rajwinder Lehal, et al.. (2012). Generation and characterization of a Notch1 signaling‐specific reporter mouse line. genesis. 50(9). 700–710. 13 indexed citations
18.
Mernier, Guillaume, Rodrigo Martínez‐Duarte, Rajwinder Lehal, Freddy Radtke, & Philippe Renaud. (2012). Very High Throughput Electrical Cell Lysis and Extraction of Intracellular Compounds Using 3D Carbon Electrodes in Lab-on-a-Chip Devices. Micromachines. 3(3). 574–581. 30 indexed citations
19.
Liu, Jeff C., Tao Deng, Rajwinder Lehal, Jinny Kim, & Eldad Zacksenhaus. (2007). Identification of Tumorsphere- and Tumor-Initiating Cells in HER2/Neu-Induced Mammary Tumors. Cancer Research. 67(18). 8671–8681. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucile Canterel-Thouennon Breakdown of academic impact, for papers by Ryan Ward Breakdown of academic impact, for papers by Sara Nik Breakdown of academic impact, for papers by Françoise Pujol Breakdown of academic impact, for papers by Jun‐ichi Suehiro Breakdown of academic impact, for papers by Anuradha Poonepalli Breakdown of academic impact, for papers by Nalle Pentinmikko Breakdown of academic impact, for papers by Joachim Theilhaber Breakdown of academic impact, for papers by Jessica Gosio Breakdown of academic impact, for papers by Nan Sethakorn
Rankless by CCL
2026